Humana (NYSE:HUM) Upgraded by Zacks Research to “Strong-Buy” Rating

Zacks Research upgraded shares of Humana (NYSE:HUM) from a hold rating to a strong-buy rating in a research report report published on Monday,Zacks.com reports.

Other analysts have also issued reports about the company. Guggenheim raised their target price on Humana from $252.00 to $269.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. upped their price target on shares of Humana from $214.00 to $316.00 and gave the stock a “neutral” rating in a research report on Monday, June 8th. The Goldman Sachs Group increased their price objective on shares of Humana from $158.00 to $195.00 and gave the stock a “sell” rating in a report on Thursday, April 30th. Piper Sandler restated a “neutral” rating and issued a $254.00 price objective (up from $182.00) on shares of Humana in a research report on Wednesday, May 13th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Humana in a research note on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Humana has an average rating of “Hold” and an average price target of $325.87.

Humana Stock Up 0.2%

NYSE HUM opened at $406.70 on Monday. The firm has a market cap of $48.83 billion, a PE ratio of 43.50, a price-to-earnings-growth ratio of 2.31 and a beta of 0.71. Humana has a one year low of $163.11 and a one year high of $415.00. The stock’s 50 day simple moving average is $345.52 and its 200 day simple moving average is $257.26. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.77 and a quick ratio of 1.77.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The firm had revenue of $39.65 billion during the quarter, compared to analysts’ expectations of $39.37 billion. During the same period last year, the firm posted $11.58 EPS. The business’s revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, sell-side analysts forecast that Humana will post 9.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humana

Hedge funds have recently added to or reduced their stakes in the company. Tema ETFs LLC increased its position in Humana by 7.5% in the second quarter. Tema ETFs LLC now owns 2,071 shares of the insurance provider’s stock worth $823,000 after purchasing an additional 145 shares during the period. Harrell Investment Partners LLC acquired a new position in Humana during the 2nd quarter valued at about $224,000. Revolve Wealth Partners LLC acquired a new position in Humana during the 2nd quarter valued at about $442,000. Centurion Wealth Management LLC bought a new position in shares of Humana in the 2nd quarter valued at about $321,000. Finally, Valeo Financial Advisors LLC bought a new position in shares of Humana in the 2nd quarter valued at about $281,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.